The thing that continues to get under my skin is Perrin's $2M salary. While all of his shareholders are losing their #$%$, he's making $2M - just not a good sign about giving a damn about shareholders. The guy should either be fired or at the very least his salary needs to be cut by at least 50% until he can prove he can create value for his shareholders - so far which he has failed miserable at!
Did you notice his disclaimer? He gets paid between $2k and $5k per month for each of the companies. I counted 72 companies - that's between $1.7M and $4.3M this guy is raking in annually. Wish I had noticed that before. To say the least, his judgment is clouded. Additionally, he's been dead wrong on NVIV.
Looks like you're going to have the opportunity to buy in the $4's....so load the boat!!!
So why has the market not recognized your rosy predictions? Company has stated they will reach full enrollment by year's end. Current enrollment rate is only 1 patient every 2+ months. Perhaps this is the problem with the lousy stock performance. To reach full enrollment by year's end, management needs to start enrolling more than two patients each month. They've already lost credibility in my book with some of the bonehead decisions. Enrollments need to dramatically pick up, otherwise they will lose any credibility they already have - which isn't much! A pickup in enrollments will hopefully gain credibility among investors that the device can find a big enough market out there once it is approved.
July Silver powered out to a new high close today and the next resistance target is a full $1.00 higher. June Gold is still the caboose on this bullish train, but it looks okay and headed for 1317.... bottom line - GPL will soon be priced above $3.00
Here's a well thought through, educated answer to your post.... The Company still hopes to finish enrollment of the remaining 13 subjects by the end of this year. While at the current pace this completion of enrollment of 13 more by the end of this year seems hard to believe, having a 5th success even before then seems quite likely. However, the Company needs to speed up enrollments to gain credibility that the device can find a big enough market out there once it is approved ... i.e., that there are indeed 3,000-4,000 potential uses per year, or the financial model projections we’ve seen don't hold water.
How many more months or years are we to use the word "hopefully" in our comments about our investment in NVIV? That's starting to wear very thin.
Believe me - I go back that far too.... Tuesday's gains have all but evaporated - only took two days and now we're back below both the 9- and 20-dma....pathetic!!
that we're dealing with a seriously flawed stock and for anyone on this board to say that NVIV is a risk free investment is simply unbelievable. The vast majority of NVIV investors who have owned this stock for any length of time at all are seriously in the red. Once again the stock is resuming its same old trading pattern. Good news brings in a rush of buying for a one day advance and then the selling continues. Tuesday's buying took us to a high of $7.10, closing back above the 50dma for the first time in over a week. We stayed above the 50-day for two whopping days and now today we are once again trading back below the 50-day at $6.50 so if you were the unfortunate soul who bought NVIV on Tuesday at $7.10, you're already down 8.45%. Based on the trading history of NVIV over the last several years, I'm beginning to think that not even FDA approval will save us!
CEO compensations versus stock performance & market cap......
Supernus Pharmaceuticals (SUPN - $17.54) among the fastest growing biotech company's in the U.S. with 70% annualized EPS growth over the next five years. EPS expected to grow from $.32 in 2014 to $2.06 by 2018. CEO Jack A Khathar's annual salary $916k. Stock is up 257% from a 2013 low of $4.90. Market Cap $866M
Pacira Pharmaceuticals (PCRX - $60.06) annualized EPS growth of 77% over the next 5 years...expected to increase EPS from $.37 per share in 2014 to $4.35 BY 2018. Full time employees 487 - CEO David Stack's annual salare $1.22M. Stock up 213% from 2013 low of $19.12. Market Cap $2.23B
Ligand Pharmaceuticals (LGND - $130.11) annualized EPS growth of 45%. Stock up 546% from 2013 low of $19.12. CEO John Higgins annual salary $945k. Market Cap $2.7B
Anavex Life Sciences (AVXL - $6.06) Alzheimer's drug in clinical trials. CEO Christopher Missling's annual salary $1.37M. Stock up 1,217% from a 2013 low of $.46. Market Cap $216M
Kite Pharma (KITE - $49.06) Stock up 129% from a 2013 low of $21.39. CEO Dr, Arie Belldegrun's annual salary $863k. Clinical stage biotech company. Market Cap $2.45B
InVivo Therapeutics (NVIV - $5.98) Stock uo 35% from 2013 low of $4.40 but down 75% from its 2013 high. CEO Mark Perrin's annual salary $1.92M. NVIV's market cap is the lowest of the group - less than one-tenth the market caps of PCRX, LGND and KITE. NVIV's stock performance is the worst in the group yet Mark Perrin's salary is the highest in the group.
The performance of a publicly traded company's stock reflects the success or failure of management. If management has been successful in reflecting progress on the earnings, revenues, bringing products to market or whatever, the price of said company's stock will reflect management's successes by increasing in value. On the other hand, if management has been unsuccessful, the stock's lack of performance will be reflected in the open market by trading lower.
I need not remind you where InVivo fits in this picture. While most everyone who owns your stock is down, Mark Perrin decided to give himself a pay raise and now makes close to $2M annually. If NVIV were priced in the teens or twenties, I could understand a pay raise, but with NVIV trading 40% below levels of four years ago and 45% below levels of less than 60 days ago, and 75% below all-time highs less than three years ago, the fact Mr. Perrin has decided to take a huge pay raise tells me he could care less about the retail shareholders who have supported this company from day one.
While there is no disagreement that progress has been made on the scaffold trials, there is also no disagreement that the performance of your stock has been a complete failure. I'm personally starting to wonder just how much lower NVIV can trade. So while your president is living the life of luxury, making $1,920,101 in annual compensation literally all of his shareholders are losing money. This doesn't sit well with me. And it doesn't look good for any potentially new shareholders who are considering purchasing you stock when they see the president is making $1.9M while the stock that reflects his performance is down 40% from four years ago and down 75% from its 2013 high less than three years ago! Frankly, it's appalling!!
P.S. Brian's reply was that he would pass it on! At least he replied. On another note, my timing models have NVIV making a bottom this week. Hopefully, I'm right and hopefully today's low was the bottom
The main way to evaluate management's performance is based on the performance of the stock. In that regard my grade is an F-. This stock is now down 43% since just prior to the announcement of the secondary. It's down 41% from where it was trading this time four years ago and it's down 18% since the beginning of the year. There is no other grade you can give this management team, led by Perrin, than an F. The fact that Perrin received a health pay raise while all of his investors are sucking wind is a crime. A resounding NAY for me.
This thing has turned into a total disaster...can't even hold the slightest of gains and then it's lower once again. Perrin should be fired
Based on the way NVIV traded 2 or 3 days before the secondary was announced and the continued selling after the secondary (almost 5 million shares over a six day period of mostly selling), there is no question that the crooks at Raymond James blew out most of the stock they owned so I doubt very seriously they will ever initiate coverage on NVIV. Over that six day stretch, NVIV averaged almost 1M shares of mostly selling every day. As most of you know, lately we struggle to trade 200,000 shares each day. While it can certainly be argued that the company has made progress under Perrin's direction, in the case of RJ secondary, he screwed us retail investors. There is no way he can justify raising $30M and at the same time losing well over $100M in market cap since the secondary was completed.
This stock is not about relaxation! Hard to relax when it's down 42% in the last six weeks. Whether fooledby has been registered on this board for 4 months or 30 days doesn't matter. All his points are legitimate. I've been a registered member for 16 years and never have I ever been involved with a stock like this one. If you have bought NVIV on any of its run-ups thinking it was headed higher, you have been severely punished - each and every time! Management could care less about the retail investors who have supported the company. If you bought on the run-up just 6 short weeks ago, you've lost 40% of your investment. If you've tried to be a "long-term" investor in NVIV you've been killed. In my view, the only winners in the last three years were the aholes at Raymond James who got their fees and then blew their stock out by shorting it before the secondary and then selling EVERY share they owned immediately after the secondary - at the expense of all retail investors. Perrin took in $30M but he has lost well over $100 million in market cap since his idiotic decision. Tell me please how you justify this decision!!!!!!
Shorts won't get off our back. In the last hour of trading, the volume exceeded the volume of the previous 5 1/2 hours. They walked in down from $6.29 to $6.15 from 2pm cst to 2:45pm cst on only 14k shares and then in the last 15 minutes someone dumped 75,285 shares on the market sucking away most of the day's gains.
Oh man! Typical fade into the close but still extremely grateful we closed in the green even if it was only $.08 cents. To say that NVIV as been a challenging investment would be a gross under statement!
Remember my post the other day comparing the possibilities of NVIV to CPXX? At the time, CPXX was trading around $13 - another developmental stage biotech company. The stock had been trading at $2 and then positive news sent it skyrocketing to $13. More positive news today has the stock up $1.69 at $16.74. In the last 30 days, CPXX is now up 737%.....oh to day dream!